Ascendis Pharma A (ASND) Payables (2012 - 2026)

Ascendis Pharma A has reported Payables for 15 years, with the latest figure at $616.7 million in Q1 2026.

• Quarterly Payables rose 9.81% year-over-year to $616.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $616.7 million (up 9.81% YoY) and the FY2025 annual result came in at $605.4 million, up 2.15% from the prior year.
• Payables climbed to $616.7 million in Q1 2026 per ASND's latest filing, from $605.4 million in the prior quarter.
• Over five years, Payables peaked at $730.5 million in Q3 2023 and troughed at $498.5 million in Q4 2022.
• A 5-year average of $596.8 million and a median of $592.6 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2024: Payables surged 1048.72% in 2022, then declined 25.23% in 2024.
• Over 5 years, Payables stood at $498.5 million in 2022, then grew by 8.28% to $539.8 million in 2023, then rose by 9.8% to $592.6 million in 2024, then rose by 2.15% to $605.4 million in 2025, then rose by 1.87% to $616.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $616.7 million, $605.4 million, and $590.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.